CPE points : 2 per article (after reading the article and passing the post-reading quiz - Pass mark 60%)

Download article (Web version) : 

Drugs & Therapeutics Review of Current CAR-T Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Adults: Tisagenlecleucel (Kymriah®) and Axicabtagene Ciloleucel (Yescarta®)

Full article (PDF) :

/ufiles/userfiles/files/Drugs%20%26%20Therapeutics%20Review%20of%20Current%20CAR-T%20Therapy%20for%20Relapsed_Refractory%20Diffuse%20%20Large%20B-Cell%20Lymphoma%20in%20Adults_%20Tisagenlecleucel%20(Kymriah%C2%AE)%20and%20%20Axicabtagene%20Ciloleucel%20(Yescarta%C2%AE)%20(2).pdf

Attempt quiz :

The dealine has passed. No more attempt is allowed.

Submission deadline: 30 November 2025, 23:59

N.B. Self-study limited to 7 CPE points per cycle with reflective report (or certificate of passing a post-quiz), or limited 3 CPE points per cycle without reflective report